Abstract:Background
Intrauterine adhesions (IUAs) are one of the main reproductive system diseases in women worldwide. Fusion between the injured opposing walls leads to partial-to-complete obliteration of the cavity and/or cervical canal. The main clinical manifestations in case of IUAs are menstrual disturbances, cyclic pain and reproductive disorders. The reproductive outcomes of women with IUAs remain limited and inefficient compared to women without IUAs, even after adhesiolysis. An exact understan… Show more
“…For patients who agreed to join the study, an outpatient hysteroscopy was performed within 6–20 weeks from their initial USG-MVA or EVA procedure by a designated team of experienced gynaecologists with similar surgical experience who were blinded to the women’s initial surgical procedure performed for the first-trimester miscarriage. Before OPH, a pregnancy test was performed and any recent coitus was recorded [ 6 ].…”
Section: Methodsmentioning
confidence: 99%
“…IUA can be asymptomatic or manifest as menstrual disturbances such as amenorrhea or hypoamenorrhea, dysmenorrhea, recurrent miscarriages, or infertility issues. The presence of IUA can have a negative impact on future fertility, as it can affect the successful implantation of embryos [ 6 ]. Moreover, IUA increases the rate of further miscarriages, potentially lead to abnormal placentation, fetal growth restriction, preterm delivery, and post-partum haemorrhage [ 7 ].…”
Background
Intrauterine adhesion (IUA) can arise as a potential complication following uterine surgery, as the surgical procedure may damage the endometrial stratum basalis. The objective of this study was to assess and compare the occurrence of IUA in women who underwent ultrasound-guided manual vacuum aspiration (USG-MVA) versus electric vacuum aspiration (EVA) for managing first-trimester miscarriage.
Methods
This was a prospective, single-centre, randomised controlled trial conducted at a university-affiliated tertiary hospital. Chinese women aged 18 years and above who had a delayed or incomplete miscarriage of ≤ 12 weeks of gestation were recruited in the Department of Obstetrics and Gynaecology at the Prince of Wales. Recruited participants received either USG-MVA or EVA for the management of their miscarriage and were invited for a hysteroscopic assessment to evaluate the incidence of IUA between 6 and 20 weeks after the surgery. Patients were contacted by phone at 6 months to assess their menstrual and reproductive outcomes.
Results
303 patients underwent USG-MVA or EVA, of whom 152 were randomised to ‘USG-MVA’ and 151 patients to the ‘EVA’ group. Out of the USG-MVA group, 126 patients returned and completed the hysteroscopic assessment, while in the EVA group, 125 patients did the same. The incidence of intrauterine adhesion (IUA) was 19.0% (24/126) in the USG-MVA group and 32.0% (40/125) in the EVA group, showing a significant difference (p < 0.02) between the two groups. No significant difference in the menstrual outcomes at 6 months postoperatively between the two groups but more patients had miscarriages in the EVA group with IUA.
Conclusions
IUAs are a possible complication of USG-MVA. However, USG-MVA is associated with a lower incidence of IUA postoperatively at 6–20 weeks. USG-MVA is a feasible, effective, and safe alternative surgical treatment with less IUA for the management of first-trimester miscarriage.
Trial registration
The study was registered with the Centre for Clinical Research and Biostatics- Clinical Trials Registry (CCRBCTR), which is a partner registry of the WHO Primary Registry-Chinese Clinical Trials Registry (ChiCTR) (Unique Trial Number: ChiCTR1900023198 with the first trial registration date on 16/05/2019)
“…For patients who agreed to join the study, an outpatient hysteroscopy was performed within 6–20 weeks from their initial USG-MVA or EVA procedure by a designated team of experienced gynaecologists with similar surgical experience who were blinded to the women’s initial surgical procedure performed for the first-trimester miscarriage. Before OPH, a pregnancy test was performed and any recent coitus was recorded [ 6 ].…”
Section: Methodsmentioning
confidence: 99%
“…IUA can be asymptomatic or manifest as menstrual disturbances such as amenorrhea or hypoamenorrhea, dysmenorrhea, recurrent miscarriages, or infertility issues. The presence of IUA can have a negative impact on future fertility, as it can affect the successful implantation of embryos [ 6 ]. Moreover, IUA increases the rate of further miscarriages, potentially lead to abnormal placentation, fetal growth restriction, preterm delivery, and post-partum haemorrhage [ 7 ].…”
Background
Intrauterine adhesion (IUA) can arise as a potential complication following uterine surgery, as the surgical procedure may damage the endometrial stratum basalis. The objective of this study was to assess and compare the occurrence of IUA in women who underwent ultrasound-guided manual vacuum aspiration (USG-MVA) versus electric vacuum aspiration (EVA) for managing first-trimester miscarriage.
Methods
This was a prospective, single-centre, randomised controlled trial conducted at a university-affiliated tertiary hospital. Chinese women aged 18 years and above who had a delayed or incomplete miscarriage of ≤ 12 weeks of gestation were recruited in the Department of Obstetrics and Gynaecology at the Prince of Wales. Recruited participants received either USG-MVA or EVA for the management of their miscarriage and were invited for a hysteroscopic assessment to evaluate the incidence of IUA between 6 and 20 weeks after the surgery. Patients were contacted by phone at 6 months to assess their menstrual and reproductive outcomes.
Results
303 patients underwent USG-MVA or EVA, of whom 152 were randomised to ‘USG-MVA’ and 151 patients to the ‘EVA’ group. Out of the USG-MVA group, 126 patients returned and completed the hysteroscopic assessment, while in the EVA group, 125 patients did the same. The incidence of intrauterine adhesion (IUA) was 19.0% (24/126) in the USG-MVA group and 32.0% (40/125) in the EVA group, showing a significant difference (p < 0.02) between the two groups. No significant difference in the menstrual outcomes at 6 months postoperatively between the two groups but more patients had miscarriages in the EVA group with IUA.
Conclusions
IUAs are a possible complication of USG-MVA. However, USG-MVA is associated with a lower incidence of IUA postoperatively at 6–20 weeks. USG-MVA is a feasible, effective, and safe alternative surgical treatment with less IUA for the management of first-trimester miscarriage.
Trial registration
The study was registered with the Centre for Clinical Research and Biostatics- Clinical Trials Registry (CCRBCTR), which is a partner registry of the WHO Primary Registry-Chinese Clinical Trials Registry (ChiCTR) (Unique Trial Number: ChiCTR1900023198 with the first trial registration date on 16/05/2019)
“…Внутриматочные спайки (ВМС) остаются одним из ключевых заболеваний репродуктивной системы женщин, реализующиеся за счет травматического повреждения/разрушения базального эндометриального компартмента [1,2]. При легком течении образуются тонкие синехии, тогда как при тяжелом проявлении ВМС происходит полная облитерация полости матки и (или) цервикального канала [3][4][5][6].…”
Section: Introductionunclassified
“…ВМС -многофакторный процесс с широким спектром предрасполагаю щих и причинно-следственных факторов [5,10,11]. Внутриматочные хирургические вмешательства (диагностические выскабливания слизистой полости матки и цервикального канала, гистерорезектоскопия, миомэктомия с вхождением в полость матки, аборты, в том числе повторные выскабливания при задержке остатков продуктов зачатия) представляют собой ключевые факторы риска и выявлены у 91% пациенток с ВМС [12][13][14][15].…”
Intrauterine adhesions (IUDs) are one of the unresolved and unsolved problems of modern reproductive medicine worldwide. Adhesive lesions lead to partial or complete obliteration of the uterine cavity and/or cervical canal. The main clinical manifestations of IUDs are menstrual irregularities, cyclical pain, infertility and other various reproductive disorders. Reproductive outcomes in women with IUDs remain poorly understood and difficult to verify. At the same time, there is currently no understanding of the basic mechanisms of IUD development, including the processes explaining the failures of the above complications. The problem of overcoming IUD recurrences after adhesiolysis remains far from being finally resolved. The gold-standard treatment for IUD is hysteroscopic adhesiolysis, which, however, is associated with a high frequency of complications and relapses, highlighting the need for preventive approaches to the management of IUD. The drugs with enzymatic activity inhibiting abnormal connective tissue include bovhyaluronidase azoximer created by the Russian developers back in 2005. The drug consists of two components – hyaluronidase and azoximer bromide. The former is an enzyme, and the latter is a stabilizer that prolongs the action of hyaluronidase. Several studies have shown that bovhyaluronidase azoximer causes the destruction of intrauterine adhesions and restores the endometrium status in inflammatory pelvic diseases. Due to prolonged antifibrotic effect of bovhyaluronidase, azoximer can be used to treat women with IUDs to reduce the risk of the subsequent development of adhesive process in the uterine cavity.
“…Ultrasonography is essential for preoperative mapping and guidance during surgical management of retained pregnancy tissue 20 . Blind tissue removal may lead to an incomplete and lengthy procedure, prolonged heavy bleeding and unnecessary scarring of the endometrial–myometrial junction associated with Asherman syndrome or perforation 21 . The exact position of the retained tissue within the uterine cavity can be deduced from the position of the EMV which underlies the retained tissue.…”
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.